Keywords: Biology, Models, Methods, Cancer, Biomarker
Motivation: Cancer immunotherapy with cyclic GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) agonists aims to generate an immune response by T cell priming, activation and infiltration into the tumour microenvironment leading to cell death.
Goal(s): The clinical development of STING agonists would benefit from imaging biomarkers that inform on intratumoural pharmacodynamics and potentially anti-tumour response.
Approach: Longitudinal diffusion-weighted MRI in a thyroid xenograft model indicated sustained increase in ADC as an imaging biomarker of tumour microenvironment changes following treatment with a STING agonist.
Results: The potential use of MRI as an indicator of early STING pathway related pharmacodynamic effects in situ is demonstrated.
Impact: Increased ADC is a sensitive, clinically-translatable imaging biomarker of tumour response to a STING agonist.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords